本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
JEDDAH, Saudi Arabia, May 15, 2023 /PRNewswire/ -- Under the patronage of The Custodian of The Two Holy Mosques, King Abdullah bin Abdulaziz Al Saud, the Islamic Development Bank (IsDB) Group's Annual Meetings successfully concluded, today, in Jeddah, Kingdom of Saudi Arabia. Chairman of IsDB Group and Benin’s Minister of Economy and Finance concluding the 2023 IsDB Group Annual Meetings The four-day event attracted 4,452 participants from 90 countries around the world as well as 89 leading regional and international organizations working toward sustainable development. During the event, held under the theme, "Partnerships to Fend off Crises," IsDB Group announced several projects and signed financing agreements with 24 member countries (MCs) worth US$ 5.4 billion to address pressing challenges that hinder growth in the Global South, with a focus on health, agriculture, food security, SMEs, education and humanitarian assistance, amongst others. IsDB President and Group Chairman, H.E. Dr. Muhammad Al Jasser, stated, "Over the past four days, we have reviewed development-related issues with our partners and member countries. We discussed the current situation and the future of the IsDB Group, reaching a number of important decisions in the process. The results of these annual meetings are certain to pave the way for further success to come." During the event, the IsDB Group announced several key projects and signed agreements reinforcing its commitment to financing sustainable development projects in its MCs. The IsDB Group Board of Executive Directors approved financing valued at more than US$ 558 million for six projects focusing on supporting inclusive growth and infrastructure development in MCs. The IsDB Group also launched its revamped Member Country Partnership Strategy documents for Uzbekistan, Pakistan and Niger which will activate the IsDB Group Country Engagement Framework within the respective countries to support multilateral development and growth. In another development, IsDB, as the Trustee of the Afghanistan Humanitarian Trust Fund, signed seven agreements for inclusive sustainable development projects in Afghanistan, with a total consideration of US$ 8,098,180, which includes grants from the King Salman Humanitarian Aid and Relief Center. IsDB and its international development partners also launched the second phase of its Lives and Livelihoods Fund (LLF 2.0) which aims to mobilize resources that support economic development across 32 of the less privileged MCs of the Bank. IsDB has committed a contribution of US$ 325 million in highly concessional loans to LLF 2.0, bringing the total grant contributions to the fund to US$ 200 million. The four-day event also included high-level plenary sessions, technical symposiums, and side events focusing on a wide range of topics, such as poverty alleviation, infrastructure development, women and youth empowerment, and climate action. CONTACT Walid El Majzoub TRACCS Tel: 00971-4-3672530 Email: Walid.majzoub@traccs.net His Excellency Dr. Muhammad Al Jasser, Chairman of the Islamic Development Bank (IsDB) Group, and Romuald Wadagni, minister of economy and finance of Benin at the closing press conference of the 2023 IsDB Group Annual Meetings
NEW YORK, Jan. 16, 2025 /PRNewswire/ -- Rokt, the global leader in ecommerce unlocking real-time relevancy in the moment that matters most, today announced a secondary transaction amid strong demand from new and existing investors. The company has signed a stock purchase agreement for ~US$335 million with investors including Tiger Global Management, Square Peg, Barrenjoey and SecondQuarter. Board members including Janchor Partners' John Ho, Terry Bowen and Karen Katz are also buying shares. This agreement values the business at US$3.5 billion. "Rokt has delivered exceptional growth since launching 12 years ago, with our revenue trajectory continuing to accelerate – this year achieving 43% growth year over year, reaching US$600 million," said Bruce Buchanan, CEO and co-founder of Rokt. "This was driven by outstanding performance across the Rokt Network, including our ecommerce products, our new Rokt Pay+ product, our international business, and our small and medium-sized business through AfterSell. In addition, we invested more than US$60 million in the Rokt Brain, our AI and machine learning customer relevance engine, and delivered a 28% improvement in relevance." "Rokt is a trusted and valuable partner to a significant – and growing – roster of clients across the globe," said Griffin Schroeder, Partner at Tiger Global. "We're pleased to increase our investment as they continue to deliver for their customers." "Over the past six years, Rokt has grown revenue 10 times and invested heavily in product and network, while still maintaining profitability," continued Buchanan. "Following significant inbound investor interest, we are thrilled to be able to offer employees and early investors access to over $100 million in liquidity." Rokt is also delighted to announce Anita Sands, Ph.D., is joining Rokt's Board of Directors. Dr. Sands is a US-based investor, advisor and speaker who serves on the boards of numerous public and private companies, including ServiceNow and Nubank, where she is Lead Independent Director. Prior to this, she had a career spanning financial services and technology, including serving as Group Managing Director and Chief Operating Officer of UBS Wealth Management Americas. "Rokt is transforming ecommerce through relevancy and enabling companies across verticals and across the globe to tap new revenue streams," said Dr. Sands. "I'm extremely pleased to join the Rokt board at such an exciting moment and to work closely with the leadership team as it propels the company to new heights." About Rokt Rokt is the global leader in ecommerce, unlocking real-time relevancy in the moment that matters most. The company's AI- and ML-powered Rokt Brain and ecommerce Rokt Network will power more than 6.5 billion transactions connecting 400 million customers across the world's leading companies, including Live Nation, Macy's, AMC Theatres, PayPal, Uber, Hulu, Staples, Albertsons and HelloFresh. mParticle by Rokt is the central nervous system providing real-time data activation to unlock value across ecommerce, advertising and customer engagement. Rokt has achieved consistent annual growth of more than 40% across the past decade, driven by its unique partnership model that returns $7 from every $8 of value back to partners. Rokt is headquartered in New York City. The company has offices in 10 global locations and serves clients throughout North America, Europe and Asia-Pacific, solidifying its position as a key player in the global ecommerce ecosystem. To learn more, visit Rokt.com. For media inquiries, please contact: Sarah Fisher, VP Communicationssarah.fisher@rokt.com Logo - https://mma.prnasia.com/media2/2353909/Rokt_Logo.jpg?p=medium600
STAMFORD, Conn., Jan. 13, 2025 /PRNewswire/ -- Trillium Flow Technologies ("Trillium"), a portfolio company of First Reserve, and a global designer, manufacturer, and aftermarket services provider of highly engineered valves and pumps used in critical infrastructure sectors such as nuclear power, water, wastewater, and industrial processing, is pleased to announce the successful completion of its refinancing in December 2024. The refinancing provides Trillium with extended maturity, enhanced liquidity, improved terms, and increased flexibility to support further M&A activity. Kerem Yilmaz, Chief Financial Officer of Trillium, commented: "We are pleased to cap a successful 2024 with this significant milestone and to enter 2025 with strong momentum. We are excited about our new credit facility, which is led by funds managed by Blue Owl Capital Inc. ("Blue Owl"). We would also like to thank JP Morgan and BDTMSD for their continued commitment and support of our business. This refinancing positions us well to execute our organic growth strategy, which includes investing in innovation and operational excellence to better serve our customers. We aim to remain active in M&A as a leading player in the flow control industry." Matt Tier, Managing Director at Blue Owl, said: "Trillium has a long and successful track record as a global supplier and aftermarket service provider of mission-critical valves and pumps used in a variety of industries. We are excited to welcome Trillium as borrower in our direct lending portfolio and look forward to supporting Doug, Kerem and the rest of the leadership team as they execute on their growth strategy for the business in the years to come." Doug Kitani, Chief Executive Officer of Trillium, said: "I'd like to extend my deepest gratitude to our finance team, equity partner First Reserve, and our lead lender, Blue Owl, for their support throughout this successful refinancing, and I especially want to recognize our employees for their exceptional performance in 2024. This milestone reflects our collective dedication and positions Trillium for continued innovation, growth, and leadership in the global flow control industry." About Trillium Flow TechnologiesTrillium Flow Technologies is a global designer, manufacturer, and aftermarket services provider specializing in highly engineered valves, pumps, and related products. Serving customers in critical infrastructure industries, Trillium is committed to delivering innovative solutions that enhance reliability, safety, and efficiency. For more information, visit: www.trilliumflow.com. About Blue OwlBlue Owl (NYSE: OWL) is a leading asset manager that is redefining alternatives. With $235 billion in assets under management as of September 30, 2024, we invest across three multi-strategy platforms: Credit, GP Strategic Capital, and Real Estate. Anchored by a strong permanent capital base, we provide businesses with private capital solutions to drive long-term growth and offer institutional investors, individual investors, and insurance companies differentiated alternative investment opportunities that aim to deliver strong performance, risk-adjusted returns, and capital preservation. Together with over 1,050 experienced professionals, Blue Owl brings the vision and discipline to create the exceptional. To learn more, visit www.blueowl.com. About First Reserve:First Reserve is a leading global private equity firm investing across diversified energy, utility, and industrial end-markets. Founded in 1983, First Reserve has more than 40 years of industry insight and has cultivated a differentiated network of global relationships. The firm has raised over $34 billion of aggregate capital and has developed operational expertise built from over 750 transactions, including platform investments and add-on acquisitions. For more information, visit www.firstreserve.com. Media ContactChris MolineauxGlobal Marketing and Communications Director, Trillium Flow Technologiesmedia@trilliumflow.com
- R-Bridge will provide bespoke financing of US$40 million with a synthetic royalty structure and flexible repayment terms - Financing will accelerate Mirxes, Singapore-based miRNA tech company's innovation and commercialization of cancer early detection solutions in new markets - Transaction underscores R-Bridge's commitment to advancing life sciences innovations and expanding access to high-quality medical care SINGAPORE, Jan. 13, 2025 /PRNewswire/ -- CBC Group's R-Bridge Healthcare Fund ("R-Bridge") announces a US$40 million structured financing transaction with Mirxes Pte Ltd., a Singapore-based miRNA technology company specializing in cancer early detection and precision medicine. The financing will provide critical support for Mirxes' ambitious growth and expansion into key global markets. Mirxes is a pioneer in developing and commercializing accurate, non-invasive and affordable blood-based miRNA tests for the early detection of cancer and other diseases. Its proprietary product, GASTROClearTM, is the world's first and only In Vitro Diagnostics ("IVD") product that has obtained regulatory approval for gastric cancer screening. With a proven 87.5% sensitivity for stage 1 cancers and 75% sensitivity for lesion sizes under 1 cm, GASTROClearTM has set a new benchmark in cancer early detection since the regulatory approval obtained in Singapore in 2019. Furthermore, Mirxes' recently completed 9,472-strong prospective clinical trial in China demonstrated superior performance on the safety and effectiveness of GASTROClearTM as a novel, accurate and accessible screening solution for gastric cancer. Mirxes continues to expand its innovative miRNA technology platform, supported by an industry-leading portfolio of over 90 patents and applications. Mirxes is also developing diagnostic solutions for lung, liver, and colorectal cancer, with a strong focus on ramping up operations in high-growth Asia Pacific markets, including Southeast Asia, China and Japan. The US$40 million synthetic royalty-backed financing provided by R-Bridge is long-term with flexible and customized repayment schedule to meet Mirxes' near-term strategic priorities. Proceeds from the financing will further accelerate its commercialization efforts in new markets and enable further innovation in its RNA diagnostic technologies. As the largest healthcare-dedicated asset management firm in Asia, CBC Group manages over US$9 billion of assets. Founded in February 2020, R-Bridge is Asia's first and only healthcare-dedicated structured financing fund, specializing in providing financing solutions backed by royalties and other cash flows. Dr. Michael Keyoung, Senior Managing Director & Head of Private Credit and Royalty at CBC Group, said, "With Asia's aging population along with other factors driving higher cancer incidence, the need for better and earlier cancer detection has become increasingly more urgent and important especially for gastric cancer which is more prevalent among Asian population. By providing this strategic financing, we are enabling Mirxes to scale its innovative miRNA technology platform globally, with potential to revolutionize cancer screening and diagnosis. This financing underscores our mission to support pioneering healthcare solutions that advance innovation and improve lives worldwide." "The escalating clinical and socio-economic burden of cancer is driving demand for accurate and accessible cancer early detection tests. We are proud to partner with R-Bridge, who shares a common mission, to deploy innovative cancer screening tests to save lives and healthcare costs," said Dr. Zhou Lihan, Co-Founder and CEO, Mirxes. "This bespoke, synergistic and multi-faceted partnership with CBC Group is timely and critical to drive Mirxes' commercial expansion in Asia-Pacific markets and to accelerate our clinical pipeline development." About CBC Group and R-Bridge Fund R-Bridge Healthcare Fund is an affiliate of CBC Group, Asia's largest healthcare-dedicated asset management firm with an AUM of $9 billion, headquartered in Singapore with offices in U.S., Asia, and Europe. With a diversified, multi-product strategy, CBC Group focuses on platform- building, buyout, private credit and royalties, and real estate, across the healthcare space, including pharmaceutical, biotech, medical technology, and healthcare services. R-Bridge was founded in 2020 to provide alternative, non-dilutive financing for healthcare companies backed by royalties, revenue interests and other cash flow generated by sales of healthcare products and services in Asia as well as globally, with the intent to generate attractive and non-correlated returns for investors. R-Bridge raised its inaugural fund in 2020 and is currently investing from its successor fund, RBF II. For more information on CBC Group, please visit www.cbridgecap.com/.Connect with us on LinkedIn (CBC Group). About Mirxes Founded and headquartered in Singapore since 2014, Mirxes is a leading RNA technology company committed to saving lives and reducing healthcare burden through innovative, accurate and accessible cancer early detection tests. Leveraging our proprietary, industry- leading miRNA detection platform, we have pioneered GASTROClear, a regulatory approved, first- and best-in-class blood In Vitro Diagnostic test for screening of gastric cancer. In collaboration with globally renowned academic clinical institutions, we have developed a maturing clinical pipeline of single and multi-cancer tests that covers high incidence and mortality cancers including Lung, Colorectal, Liver, Breast and Pancreatic cancers. Mirxes is commercializing our PCR and NGS based portfolio tests in Southeast Asia, China, Japan and US, supported by an integrated in-house capability of R&D, IVD product manufacturing and clinical diagnostic laboratory services. For more information, visit https://mirxes.com/.Follow us on LinkedIn, Facebook and Instagram.
Funding from leading investors to accelerate R&D and international expansion to make robotic surgery solutions accessible to more HONG KONG, Jan. 13, 2025 /PRNewswire/ -- Cornerstone Robotics (the "Company"), a leading global innovator in surgical robotics, today announced that it has successfully raised over US$70 million in Series C financing led by EQT with participation from Qiming Venture Partners, Alpha JWC Ventures, the Innovation and Technology Venture Fund, eGarden Ventures, CTS Funds, K2VC, Long-Z Capital, etc. This funding will accelerate the Company's efforts in advancing the commercialization process, developing new surgical robotics products, conducting clinical trials, obtaining regulatory approvals, and promoting global adoption of advanced robotic surgical solutions. In addition to receiving funding from a group of prominent investors, the Company headquartered in Hong Kong and the Greater Bay Area, also received investment from the Innovation and Technology Venture Fund under the Innovation and Technology Commission of the Hong Kong Special Administrative Region Government. The endorsement underscores confidence for Cornerstone Robotics' product innovation and global commercialization capabilities. This backing will further enable the Company to expand into key geographies, including countries in Europe, Southeast Asia and across global markets. Since its establishment in September 2019, Cornerstone Robotics has aimed to revolutionize healthcare by making advanced surgical systems accessible globally. Through in-house R&D and vertical supply chain integration, Cornerstone Robotics delivers high-quality performance at competitive prices, enabling partnerships with leading medical centers in mainland China, Hong Kong, and Europe, including the Faculty of Medicine of the Chinese University of Hong Kong, and Chinese University of Hong Kong-Shenzhen Medicine. The Company's successful clinical trials in multiple specialties – including urology, general surgery, gynecology and thoracic surgeries – have built a solid foundation for international expansion. In September 2024, Cornerstone Robotics achieved a significant milestone when it obtained the National Medical Products Administration (NMPA) approval in China for "Sentire", its pioneering Endoscopic Surgical System. Additionally in 2024, Cornerstone Robotics established a site in the UK. This collaboration aims to foster cutting-edge innovation, support advanced research, and enhance the Company's ability to serve patients in Europe and across global markets. Professor Samuel Au, founder and CEO of Cornerstone Robotics, stated, "Cornerstone Robotics experienced several pivotal milestones over the past year. We are deeply grateful to our shareholders for their trust and support. This milestone is not only a recognition of our team's efforts in translating surgical robotics innovations into practical applications but also a testament to our commitment to long-term, high-quality development. 'Building the cornerstone of surgical robotics industry' has been our aspiration since we began in 2019. After five years of efforts, we have achieved independent R&D and manufacturing, also received recognition from the NMPA in 2024. Moving forward, our team will continue to innovate, expand global markets, advance international certifications, and collaborate with more partners to create value for the intelligent healthcare industry and contribute to a better future for humanity." Excerpts from Investment Institutions' Remarks [EQT] Clara Ho and Gordon Shaw, Partners in the EQT Private Capital Asia advisory team, said, "Globally, there is an urgent need to make high-quality robot-assisted surgical care accessible to patients, yet few companies have the capability to deliver the level of safety, precision, and rigor required for these critical procedures. Cornerstone Robotics stands out as a leader in this space, combining cutting-edge medical robotics with a focus on expanding access to care. EQT is proud to support Cornerstone Robotics by leveraging our deep expertise in healthcare, technology, and life sciences to help advance their mission of providing innovative and cost-effective surgical solutions to patients worldwide." [Qiming Venture Partners] William Hu, Managing Partner of Qiming Venture Partners, said, "The development and clinical application of surgical robots continue to drive improved treatment outcomes. Since Qiming Venture Partners' investment in Cornerstone Robotics, we have observed steady enhancements in the company's product performance and the continuous growth of its team. We believe Cornerstone Robotics is well-positioned to deliver increasingly competitive products and greater clinical value to customers worldwide. We are delighted to continue our investment and support as we work together toward new milestones." [Alpha JWC Ventures] Jefrey Joe, General Partner Alpha JWC Ventures, said, "Alpha JWC Ventures is excited to partner with Cornerstone Robotics in their journey to expand into Southeast Asia. We believe their innovative approach to surgical robotics aligns with the growing needs and opportunities in the healthcare sector. We are committed to supporting their growth and success to bring the highest standards of healthcare in the region." The financial advisor to the Company is UBS. About Cornerstone Robotics Cornerstone Robotics (CSR) is dedicated to delivering accessible surgical systems that allow patients around the world to benefit from the highest standards of care. Our first-generation Endoscopic Surgical System is developed entirely in-house and has received approval by China's National Medical Products Administration (NMPA). With multiple manufacturing facilities established in Greater Bay Area and corresponding supply chain support, we offer safe and accessible surgical robots to the world. To find out more information, please visit our website at https://www.csrbtx.com/en/ . About EQT EQT is a purpose-driven global investment organization with EUR 246 billion in total assets under management (EUR 134 billion in fee-generating assets under management), divided into two business segments: Private Capital and Real Assets. EQT owns portfolio companies and assets in Europe, Asia Pacific, and the Americas and supports them in achieving sustainable growth, operational excellence, and market leadership. More info: www.eqtgroup.com Follow EQT on LinkedIn, X, YouTube and Instagram About Qiming Venture Partners Qiming Venture Partners was founded in 2006. Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companies in the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages. Since our debut, we have backed over 580 fast-growing and innovative companies. Over 210 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 80 portfolio companies that have achieved unicorn or super unicorn status. About Alpha JWC Ventures Alpha JWC Ventures is an early to growth-stage Southeast Asian venture capital firm. Its debut fund was launched in 2015 as Indonesia's first independent and institutional early-stage venture capital fund. Over the years, Alpha JWC has established a strong reputation and clear positioning in the market as the leading venture capital firm with one of the region's largest on-the-ground teams and a global network. The firm currently manages around US$ 650 million AUM – the largest early-stage fund in Southeast Asia – and 80+ active portfolio companies across Southeast Asia. For more information, please visit https://www.alphajwc.com. About Innovation and Technology Venture Fund Innovation and Technology Venture Fund (ITVF), under the Innovation and Technology Commission of the Hong Kong Special Administrative Region Government, co-invests with venture capital funds selected as ITVF's co-investment partners (CPs) at a matching ratio of approximately 1 (ITVF): 2 (CP) in eligible local innovation and technology (I&T) start-ups to enrich the local I&T ecosystem. The ITVF enhanced scheme has been also launched to invest in start-ups of strategic industries. To find out more information, please visit the website at https://www.itf.gov.hk/l-eng/ITVF.asp About eGarden Ventures eGarden Ventures is a venture capital firm specializing in early growth-stage companies within emerging sectors. We are committed to supporting dedicated startup founders, providing not only financial investment but also strategic resources and guidance to help businesses thrive post-investment. About CTS Capital CTS Capital is a multi-stage healthcare and life sciences investment institution. Managed by a team of seasoned professionals with deep insights into the healthcare industry and extensive expertise in private equity, CTS Capital is committed to partnering with exceptional entrepreneurs and scientists, and actively engaging in the growth of its portfolio companies to drive technological and commercial innovations in China's healthcare sector and the global market. Guided by a research-driven investment strategy, CTS Capital's investment focus spans biotechnology, innovative therapeutics, innovative medical devices, precision diagnosis, healthcare services, and other cutting-edge technologies within the broader healthcare landscape. Since its inception, CTS Capital has invested in several leading companies in their respective sectors, many of which have achieved successful public listing, including United Imaging (688271.SH), SinoCellTech (688520.SH), SinoBiological (301047.SZ), Giant Biogene (02367.HK), and Recbio (02179.HK). About KV2C Founded in 2010, K2VC is an early-stage venture capital firm devoted to promoting technology advancement, indutrial upgrade, business model innovation and consumer lifestyle revolution. K2VC manages both RMB and USD funds, with AUM over 10 billion RMB and 700 portfolios companies year to date. The English name of K2VC, comes from the abbreviation of Mount chhogo ri. K2 is the second highest mountain in the world and known for being the most difficult to climb, which symbolizes the great pursuit of entrepreneurs to surpass themselves and challenge their limits. K2 wishes to be a mountain guide for the entrepreneurs, accompany them in every step of the climb, overcome the difficult and reach the peak. K2VC manages two funds, K2 Angel Partners and K2 Venture Partners. Besides venture capital investment, K2 also promotes social progress by funding Non-for-profit organizations and social enterprises. About Long-Z Capital Founded in 2017, Long-Z Investments focuses on investment in the consumer and technology industries and strives to become an important supporter of top entrepreneurs in these two industries. Rooted in Meituan ecosystem, we boost unique and rich industrial resources and advantages. At present, we have managed three RMB funds and one USD fund, with funds under management exceeding 13 billion yuan. The investors include government-guided funds, the world's top sovereign funds, pension funds, well-known FOFs, leading enterprises in the consumer industry, internet companies, alumni donation funds and well-known professional institutions. Since establishment eight years ago, we have invested in dozens of member enterprises, including Li Auto, Cornerstone Robotics, ProfoundBio, MIXUE Ice Cream & Tea, Good Me, HEYTEA, Manner Coffee, Moonshot AI, Unitree Robotics, Del Technology, RongSemi, Axera, EcoFlow and SICHAIN, etc.
Funding from leading investors to accelerate R&D and international expansion to make robotic surgery solutions accessible to more HONG KONG, Jan. 13, 2025 /PRNewswire/ -- Cornerstone Robotics (the "Company"), a leading global innovator in surgical robotics, today announced that it has successfully raised over US$70 million in Series C financing led by EQT with participation from Qiming Venture Partners, Alpha JWC Ventures, the Innovation and Technology Venture Fund, eGarden Ventures, CTS Funds, K2VC, Long-Z Capital, etc. This funding will accelerate the Company's efforts in advancing the commercialization process, developing new surgical robotics products, conducting clinical trials, obtaining regulatory approvals, and promoting global adoption of advanced robotic surgical solutions. In addition to receiving funding from a group of prominent investors, the Company headquartered in Hong Kong and the Greater Bay Area, also received investment from the Innovation and Technology Venture Fund under the Innovation and Technology Commission of the Hong Kong Special Administrative Region Government. The endorsement underscores confidence for Cornerstone Robotics' product innovation and global commercialization capabilities. This backing will further enable the Company to expand into key geographies, including countries in Europe, Southeast Asia and across global markets. Since its establishment in September 2019, Cornerstone Robotics has aimed to revolutionize healthcare by making advanced surgical systems accessible globally. Through in-house R&D and vertical supply chain integration, Cornerstone Robotics delivers high-quality performance at competitive prices, enabling partnerships with leading medical centers in mainland China, Hong Kong, and Europe, including the Faculty of Medicine of the Chinese University of Hong Kong, and Chinese University of Hong Kong-Shenzhen Medicine. The Company's successful clinical trials in multiple specialties – including urology, general surgery, gynecology and thoracic surgeries – have built a solid foundation for international expansion. “Sentire” In September 2024, Cornerstone Robotics achieved a significant milestone when it obtained the National Medical Products Administration (NMPA) approval in China for "Sentire", its pioneering Endoscopic Surgical System. Additionally in 2024, Cornerstone Robotics established a site in the UK. This collaboration aims to foster cutting-edge innovation, support advanced research, and enhance the Company's ability to serve patients in Europe and across global markets. Professor Samuel Au, founder and CEO of Cornerstone Robotics, stated, "Cornerstone Robotics experienced several pivotal milestones over the past year. We are deeply grateful to our shareholders for their trust and support. This milestone is not only a recognition of our team's efforts in translating surgical robotics innovations into practical applications but also a testament to our commitment to long-term, high-quality development. 'Building the cornerstone of surgical robotics industry' has been our aspiration since we began in 2019. After five years of efforts, we have achieved independent R&D and manufacturing, also received recognition from the NMPA in 2024. Moving forward, our team will continue to innovate, expand global markets, advance international certifications, and collaborate with more partners to create value for the intelligent healthcare industry and contribute to a better future for humanity." Excerpts from Investment Institutions' Remarks [EQT] Clara Ho and Gordon Shaw, Partners in the EQT Private Capital Asia advisory team, said, "Globally, there is an urgent need to make high-quality robot-assisted surgical care accessible to patients, yet few companies have the capability to deliver the level of safety, precision, and rigor required for these critical procedures. Cornerstone Robotics stands out as a leader in this space, combining cutting-edge medical robotics with a focus on expanding access to care. EQT is proud to support Cornerstone Robotics by leveraging our deep expertise in healthcare, technology, and life sciences to help advance their mission of providing innovative and cost-effective surgical solutions to patients worldwide." [Qiming Venture Partners] William Hu, Managing Partner of Qiming Venture Partners, said, "The development and clinical application of surgical robots continue to drive improved treatment outcomes. Since Qiming Venture Partners' investment in Cornerstone Robotics, we have observed steady enhancements in the company's product performance and the continuous growth of its team. We believe Cornerstone Robotics is well-positioned to deliver increasingly competitive products and greater clinical value to customers worldwide. We are delighted to continue our investment and support as we work together toward new milestones." [Alpha JWC Ventures] Jefrey Joe, General Partner Alpha JWC Ventures, said, "Alpha JWC Ventures is excited to partner with Cornerstone Robotics in their journey to expand into Southeast Asia. We believe their innovative approach to surgical robotics aligns with the growing needs and opportunities in the healthcare sector. We are committed to supporting their growth and success to bring the highest standards of healthcare in the region." The financial advisor to the Company is UBS. About Cornerstone Robotics Cornerstone Robotics (CSR) is dedicated to delivering accessible surgical systems that allow patients around the world to benefit from the highest standards of care. Our first-generation Endoscopic Surgical System is developed entirely in-house and has received approval by China's National Medical Products Administration (NMPA). With multiple manufacturing facilities established in Greater Bay Area and corresponding supply chain support, we offer safe and accessible surgical robots to the world. To find out more information, please visit our website at https://www.csrbtx.com/en/ . About EQT EQT is a purpose-driven global investment organization with EUR 246 billion in total assets under management (EUR 134 billion in fee-generating assets under management), divided into two business segments: Private Capital and Real Assets. EQT owns portfolio companies and assets in Europe, Asia Pacific, and the Americas and supports them in achieving sustainable growth, operational excellence, and market leadership. More info: www.eqtgroup.com Follow EQT on LinkedIn, X, YouTube and Instagram About Qiming Venture Partners Qiming Venture Partners was founded in 2006. Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companies in the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages. Since our debut, we have backed over 580 fast-growing and innovative companies. Over 210 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 80 portfolio companies that have achieved unicorn or super unicorn status. About Alpha JWC Ventures Alpha JWC Ventures is an early to growth-stage Southeast Asian venture capital firm. Its debut fund was launched in 2015 as Indonesia's first independent and institutional early-stage venture capital fund. Over the years, Alpha JWC has established a strong reputation and clear positioning in the market as the leading venture capital firm with one of the region's largest on-the-ground teams and a global network. The firm currently manages around US$ 650 million AUM – the largest early-stage fund in Southeast Asia – and 80+ active portfolio companies across Southeast Asia. For more information, please visit https://www.alphajwc.com. About Innovation and Technology Venture Fund Innovation and Technology Venture Fund (ITVF), under the Innovation and Technology Commission of the Hong Kong Special Administrative Region Government, co-invests with venture capital funds selected as ITVF's co-investment partners (CPs) at a matching ratio of approximately 1 (ITVF): 2 (CP) in eligible local innovation and technology (I&T) start-ups to enrich the local I&T ecosystem. The ITVF enhanced scheme has been also launched to invest in start-ups of strategic industries. To find out more information, please visit the website at https://www.itf.gov.hk/l-eng/ITVF.asp About eGarden Ventures eGarden Ventures is a venture capital firm specializing in early growth-stage companies within emerging sectors. We are committed to supporting dedicated startup founders, providing not only financial investment but also strategic resources and guidance to help businesses thrive post-investment. About CTS Capital CTS Capital is a multi-stage healthcare and life sciences investment institution. Managed by a team of seasoned professionals with deep insights into the healthcare industry and extensive expertise in private equity, CTS Capital is committed to partnering with exceptional entrepreneurs and scientists, and actively engaging in the growth of its portfolio companies to drive technological and commercial innovations in China's healthcare sector and the global market. Guided by a research-driven investment strategy, CTS Capital's investment focus spans biotechnology, innovative therapeutics, innovative medical devices, precision diagnosis, healthcare services, and other cutting-edge technologies within the broader healthcare landscape. Since its inception, CTS Capital has invested in several leading companies in their respective sectors, many of which have achieved successful public listing, including United Imaging (688271.SH), SinoCellTech (688520.SH), SinoBiological (301047.SZ), Giant Biogene (02367.HK), and Recbio (02179.HK). About KV2C Founded in 2010, K2VC is an early-stage venture capital firm devoted to promoting technology advancement, indutrial upgrade, business model innovation and consumer lifestyle revolution. K2VC manages both RMB and USD funds, with AUM over 10 billion RMB and 700 portfolios companies year to date. The English name of K2VC, comes from the abbreviation of Mount chhogo ri. K2 is the second highest mountain in the world and known for being the most difficult to climb, which symbolizes the great pursuit of entrepreneurs to surpass themselves and challenge their limits. K2 wishes to be a mountain guide for the entrepreneurs, accompany them in every step of the climb, overcome the difficult and reach the peak. K2VC manages two funds, K2 Angel Partners and K2 Venture Partners. Besides venture capital investment, K2 also promotes social progress by funding Non-for-profit organizations and social enterprises. About Long-Z Capital Founded in 2017, Long-Z Investments focuses on investment in the consumer and technology industries and strives to become an important supporter of top entrepreneurs in these two industries. Rooted in Meituan ecosystem, we boost unique and rich industrial resources and advantages. At present, we have managed three RMB funds and one USD fund, with funds under management exceeding 13 billion yuan. The investors include government-guided funds, the world's top sovereign funds, pension funds, well-known FOFs, leading enterprises in the consumer industry, internet companies, alumni donation funds and well-known professional institutions. Since establishment eight years ago, we have invested in dozens of member enterprises, including Li Auto, Cornerstone Robotics, ProfoundBio, MIXUE Ice Cream & Tea, Good Me, HEYTEA, Manner Coffee, Moonshot AI, Unitree Robotics, Del Technology, RongSemi, Axera, EcoFlow and SICHAIN, etc.
A12 藝術空間
Financing agreements
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
